Bitte warten ...
 

Publikationen

2021

 

Aggressive Lymphome

  • Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
    Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR.
    N Engl J Med. 2021 Dec 14. (Online ahead of print).     PMID: 34904798 DOI: 10.1056/NEJMoa2116596
  • Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B cell–type diffuse large B-cell lymphoma
    Lorenz Thurner, Sylvia Hartmann, Moritz Bewarder, Natalie Fadle, Evi Regitz, Claudia Schormann, Natalia Quiroga, Maria Kemele, Wolfram Klapper, Andreas Rosenwald, Rainer Maria Bohle, Lorenz Trümper, Anna Nimmesgern, Christina Körbel, Matthias W. Laschke, Michael D. Menger, Stefan Barth, Boris Kubuschok, Anja Mottok, Dominic Kaddu-Mulindwa, Martin-Leo Hansmann, Viola Pöschel, Gerhard Held, Niels Murawski, Stephan Stilgenbauer, Frank Neumann, Klaus-Dieter Preuss, and Michael Pfreundschuh.
    Haematologica, 2021 Aug 1;106(8):2224-2232 PMID: 32675228 PMCID: PMC8327713 DOI: 10.3324/haematol.2019.241653
  • FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
    Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, Bewarder M, Schwier M, Pfreundschuh M, Löffler M, Menhart K, Grosse J, Ziepert M, Herrmann K, Dührsen U, Hüttmann A, Barbato F, Poeschel V, Hellwig D.
    Eur J Nucl Med Mol Imaging. 2021 Apr 29. PMID: 33928400 PMCID: PMC8440256 DOI: 10.1007/s00259-021-05348-6
  • Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
    Frontzek, F.*, Ziepert, M.*, Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, FP., Metzner, B., Staiger, AM., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G. and Schmitz, N. (2021):
    Lancet Haematol. e267-e277. PMID: 33667420 DOI: 10.1016/S2352-3026(21)00022-3
  • SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.
    Croci, GA.*, Au-Yeung, RKH.*, Reinke, S., Staiger, AM., Koch, K., Oschlies, I., Richter, J., Poeschel, V., Held, G., Loeffler, M., Trümper, L., Rosenwald, A., Ott, G., Spang, R., Altmann, B., Ziepert, M.* and Klapper, W.* (2021):  
    Ann Oncol. 32(11), 1400-09. PMID: 34438040 DOI: 10.1016/j.annonc.2021.08.1991
  • Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
    Maurer, MJ., Jakobsen, LH., Mwangi, R., Schmitz, N., Farooq, U., Flowers, CR., de Nully Brown, P., Thompson, CA., Frederiksen, H., Cunningham, D., Jørgensen, J., Poeschel, V., Nowakowski, G., Seymour, JF., Merli, F., Haioun, C., Ghesquieres, H., Ziepert, M., Tilly, H., Salles, G., Shi, Q., El-Galaly, TC. and Habermann, TM. (2021):  Am J Hematol. 96(5), 599-605. PMID: 33661547 DOI: 10.1002/ajh.26149
  • Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
    Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S.
    Blood Adv. 2021 PMID: 34196677 PMCID: PMC8288676 DOI: 10.1182/bloodadvances.2020004155
  • CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M. Blood. 2021 Jun 24:blood.2020010543. Online ahead of print. https://doi.org/10.1182/blood.2020010543
  • Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
    Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G.  Haematologica. 2021 Aug 19. Online ahead of print.PMID: 34196165 PMCID: PMC8409029 DOI: 10.3324/haematol.2020.275958

 

Indolente Lymphome

  • Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
    Bolen CR, Mattiello F, Herold M, Hiddemann W, Huet S, Klapper W, Marcus R, Mir F, Salles G, Weigert O, Nielsen T, Oestergaard MZ, Venstrom JM. Blood. 2021 May 13;137(19):2704-2707. doi: 10.1182/blood.2020008119. PMID: 33512481
  • Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
    Alig S, Jurinovic V, Shahrokh Esfahani M, Haebe S, Passerini V, Hellmuth JC, Gaitzsch E, Keay W, Tahiri N, Zoellner A, Rosenwald A, Klapper W, Stein H, Feller A, Ott G, Staiger AM, Horn H, Hansmann ML, Pott C, Unterhalt M, Schmidt C, Dreyling M, Alizadeh AA, Hiddemann W, Hoster E, Weigert O.
    Blood Adv. 2020 Sep 22;4(18):4451-4462. doi: 10.1182/bloodadvances.2020002546. PMID: 32941649 Free PMC article. Clinical Trial.
  • Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.
    Bararia D, Hildebrand JA, Stolz S, Haebe S, Alig S, Trevisani CP, Osorio-Barrios F, Bartoschek MD, Mentz M, Pastore A, Gaitzsch E, Heide M, Jurinovic V, Rautter K, Gunawardana J, Sabdia MB, Szczepanowski M, Richter J, Klapper W, Louissaint A Jr, Ludwig C, Bultmann S, Leonhardt H, Eustermann S, Hopfner KP, Hiddemann W, von Bergwelt-Baildon M, Steidl C, Kridel R, Tobin JWD, Gandhi MK, Weinstock DM, Schmidt-Supprian M, Sárosi MB, Rudelius M, Passerini V, Mautner J, Weigert O.
    Cell Rep. 2020 May 5;31(5):107522. doi: 10.1016/j.celrep.2020.107522. Epub 2020 Apr 23. PMID: 32330423
  • Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.
    Staiger AM, Hoster E, Jurinovic V, Winter S, Leich E, Kalla C, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Weigert O, Hiddemann W, Herfarth K, Rosenwald A, Engelhard M, Ott G, Horn H.
    Blood. 2020 Jan 16;135(3):181-190. doi: 10.1182/blood.2019000560. PMID: 31697802 Clinical Trial.
  • Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M; ESMO Guidelines Committee Ann Oncol. 2021 Mar;32(3):298-308
  • Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.  
    Panayiotidis P, Follows GA, Mollica L, Nagler A, Özcan M, Santoro A, Stevens D, Trevarthen D, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL, Dreyling M.
    Blood Adv. 2021 Feb 9;5(3):823-828 PMID: 33560394 PMCID: PMC7876879 DOI: 10.1182/bloodadvances.2020002910
  • Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study
    Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner CM, Zaja F, Robson S, MacGregor L, Tschopp RR, Nick S, Dreyling M..  Haematologica. 2021 Jun 17. Online ahead of print PMID: 34134469 DOI: 10.3324/haematol.2020.274803
  • Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
    Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C.
    Nat Med. 2021 Dec 17. (Online ahead of print)
  • Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.
    Buske C, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Kwak L, Kim WS, Lee S, Kim S, Ahn K, Ogura M.Blood Adv. 2021 Sep 14;5(17):3354-3361
    PMID: 34477816 PMCID: PMC8525228 DOI: 10.1182/bloodadvances.2021004484
  • Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
    Trotman J, Buske C, Tedeschi A, Matous JV, MacDonald D, Tam CS, Tournilhac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-Hisijara I, Dimopoulos MA.Clin Cancer Res. 2021 Nov 1;27(21):5793-5800.
    PMID: 34380643 DOI: 10.1158/1078-0432.CCR-21-1497

  •  

    Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
    Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, D'Sa S, Owen RG, Cull G, Mulligan S, Czyz J, Castillo JJ, Motta M, Siddiqi T, Gironella Mesa M, Granell Gorrochategui M, Talaulikar D, Zinzani PL, Askari E, Grosicki S, Oriol A, Rule S, Kloczko J, Tedeschi A, Buske C, Leblond V, Trotman J, Chan WY, Michel J, Schneider J, Tan Z, Cohen A, Huang J, Tam CS.Blood Adv. 2020 Dec 8;4(23):6009-6018.
    PMID: 33284944 PMCID: PMC7724905 DOI: 10.1182/bloodadvances.2020003010

 

 

Mantelzelllymphome

  • LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome
    Thurner L, Fadle N, Bittenbring JT, Regitz E, Schuck R, Cetin O, Stuhr A, Rixecker T, Murawski N, Poeschel V, Kaddu-Mulindwa D, Preuss KD, Stilgenbauer S, Hermine O, Kluin-Nelemans HC, Hartmann S, Dreyling M, Pott C, Bewarder M, Hoster E. 
    Blood. 2021 Jun 10;137(23):3251-3258 PMID: 33513604 PMCID: PMC8351899 (available on 2022-06-10) DOI: 10.1182/blood.2020008835
  • The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.
    Bewarder M, Kiefer M, Will H, Olesch K, Moelle C, Stilgenbauer S, Christofyllakis K, Kaddu-Mulindwa D, Bittenbring JT, Fadle N, Regitz E, Kaschek L, Hoth M, Neumann F, Preuss KD, Pfreundschuh M, Thurner L.
    Hemasphere. 2021 Jul 13;5(8):e620. PMID: 34263144 PMCID: PMC8274796 DOI: 10.1097/HS9.0000000000000620
  • The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    Roider T, Wang X, Hüttl K, Müller-Tidow C, Klapper W, Rosenwald A, Stewart JP, de Castro DG, Dreger P, Hermine O, Kluin-Nelemans HC, Grabe N, Dreyling M, Pott C, Ott G, Hoster E, Dietrich S.
    Int J Cancer. 2021      PMID: 32638373 DOI: 10.1002/ijc.33202
  • Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.
    Silkenstedt E, Linton K, Dreyling M.
    Br J Haematol. 2021 Mar 30 Online ahead of print.      PMID: 33783838 DOI: 10.1111/bjh.17419
  • Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Topp M, Truemper L, Schmidt C, Bouabdallah K, Krauter J, Lenz G, Dürig J, Vergote V, Schäfer-Eckart K, André M, Kluin-Nelemans HC, van Hoof A, Klapper W, Hiddemann W, Dreyling M, Hoster E; European Mantle Cell Lymphoma Network.   Lancet Haematol. 2021 Sep;8(9):e648-e657.
  • ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
    Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS.
    Bone Marrow Transplant. 2021 Aug 20. Online ahead of print.

 

T-Zell-Lymphome

  • A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL
    Schmitz, N., Truemper, L., Bouabdallah, K., Ziepert, M., Leclerc, M., Cartron, G., Jaccard, A., Reimer, P., Wagner, E., Wilhelm, M., Sanhes, L., Lamy, T., de Leval, L., Rosenwald, A., Roussel, M., Kroschinsky, F., Lindemann, W., Dreger, P., Viardot, A., Milpied, N., Gisselbrecht, C., Wulf, G., Gyan, E., Gaulard, P., Bay, JO., Glass, B., Poeschel, V., Damaj, G., Sibon, D., Delmer, A., Bilger, K., Banos, A., Haenel, M., Dreyling, M., Metzner, B., Keller, U., Braulke, F., Friedrichs, B., Nickelsen, M., Altmann, B.* and Tournilhac, O.* (2021):
    Blood. 137(19), 2646-56.     PMID: 33512419 DOI: 10.1182/blood.2020008825
  • Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
    Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Wilhelm C, Pezzutto A, Zijlstra JM, Neste EVD, Lugtenburg PJ, Doorduijn JK, Gelder MV, van Imhoff GW, Zettl F, Braulke F, Nickelsen M, Glass B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N, Trümper L; ACT-2 study investigators.  
    Leukemia. 2021 Jan;35(1):143-155. doi: 10.1038/s41375-020-0838-5. Epub 2020 May 7. PMID: 32382083.
  • A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL
    Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky F, Lindemann W, Dreger P, Viardot A, Milpied N, Gisselbrecht C, Wulf G, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer A, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O.
    Blood. 2021 May 13;137(19):2646-2656. doi: 10.1182/blood.2020008825. PMID: 33512419.

 

ZNS-Lymphome

  • Integration of the B-cell Receptor Antigen Neurabin-I/SAMD14 into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.
    Moritz Bewarder, Lisa Goerens, Clara Moelle, Maximilian Kiefer, Stephan Stilgenbauer, Konstantinos Christofyllakis, Dominic Kaddu-Mulindwa, Natalie Fadle, Evi Regitz, Frank Neumann, Klaus-Dieter Preuss, Michael Pfreundschuh and Lorenz Thurner.  Accepted October 2020 in Frontiers Oncology
    PMID: 33282736 PMCID: PMC7689012 DOI: 10.3389/fonc.2020.580364
  • Treatment Regiments for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review
    Schorb E, Isbell LK, Illerhaus G, Ihorst G, Meerpohl JJ, Grummich K, Nagavci B, Schmucker C.
    Cancers (Basel) 2021 Aug      PMID: 34503078 PMCID: PMC8428349 DOI: 10.3390/cancers13174268
  • Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)
    Barajas RF, Politi LS, Anzalone N, Schöder H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer D, Andronesi OC, Ferreri AJM, Mrugala MM, Grommes C, Neuwelt EA, Ambady P, Rubenstein JL, Illerhaus G, Nagane M, Batchelor TT, Hu LS. Neuro Oncol. 2021 Jul     
    PMID: 33560416 PMCID: PMC8248856 DOI: 10.1093/neuonc/noab020
  • CNS relapse in DLBCL: a calculable risk?
    Illerhaus G
    Blood. 2021 Feb 25;137(8):1120-1124. doi: 10.1182/blood.2020007236. PMID: 32877514
  • Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
    Montesinos-Rongen M, Brunn A, Tuchscherer A, Borchmann P, Schorb E, Kasenda B, Altmüller J, Illerhaus G, Ruge MI, Maarouf M, Büttner R, Hansmann ML, Hallek M, Prinz M, Siebert R, Deckert M.
    J Mol Diagn. 2020 Oct     PMID: 32745612 DOI: 10.1016/j.jmoldx.2020.07.002                            
  • High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study
    Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, Fricker H, Finke J, Illerhaus G.
    Blood Adv. 2020 Jul      PMID: 32722778 PMCID: PMC7391148 DOI: 10.1182/bloodadvances.2020002064
  • Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
    Lauer EM, Waterhouse M, Braig M, Mutter J, Bleul S, Duque-Afonso J, Duyster J, Marks R, Reinacher PC, Prinz M, Illerhaus G, Finke J, Schorb E, Scherer F.
    Br J Haematol. 2020 Jul         PMID: 32452526 DOI: 10.1111/bjh.16759
  • Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
    Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, Ninkovic S, Eyre TA, Cummin T, Smith J, Yallop D, De Marco B, Krampera M, Trefz S, Orsucci L, Fabbri A, Illerhaus G, Cwynarski K, Ferreri AJM.
    Br J Haematol. 2020 Jun             PMID: 31997308 DOI: 10.1111/bjh.16451


Forschung zu COVID-19

  • Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab.
    Igor Kos, Benedikt Balensiefer, Sophie Roth, Manfred Ahlgrimm, Martina Sester, Tina Schmidt, Lorenz Thurner, Moritz Bewarder, Robert Bals, Frank Lammert, Stephan Stilgenbauer, Dominic Kaddu-Mulindwa. Front Oncol 2020 Sep 2;10:1578.    
    PMID: 32984017 PMCID: PMC7493633 DOI: 10.3389/fonc.2020.01578

 

Arbeitsgruppenübergreifende Forschung

  • Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential.
    Bewarder M, Held G, Thurner L, Stilgenbauer S, Smola S, Preuss KD, Carbon G, Bette B, Christofyllakis K, Bittenbring JT, Felbel A, Hasse A, Murawski N, Kaddu-Mulindwa D, Neumann F.  Cancer Immunol Immunother. 2020 Apr 16.      
    PMID: 32300857 PMCID: PMC7347513 DOI: 10.1007/s00262-020-02564-1

  • Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy
    Rixecker T, Lesan V, Ahlgrimm M, Thurner L, Bewarder M, Murawski N, Christofyllakis K, Altmeyer S, Bick A, Stilgenbauer S, Bittenbring JT, Kaddu-Mulindwa D.. Bone Marrow Transplant. 2021 Jan;56(1):195-201.      PMID: 32704092 DOI: 10.1038/s41409-020-01003-0
  • Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas
    Sylvia Hartmann, Sonja Scharf, Yvonne Steiner, Andreas G. Loth, Emmanuel Donnadieu, Nadine Flinner, Viola Poeschel, Stephanie Angel, Moritz Bewarder, Julia Bein, Uta Brunnberg, Alessandro Bozzatto, Bernhard Schick, Stephan Stilgenbauer, Rainer M. Bohle, Lorenz Thurner and Martin-Leo Hansmann.. Cancers, accepted Oct 12th, 2021 Cancers . 2021 Oct 17;13(20):5208 
    PMID: 34680356 PMCID: PMC8534096 DOI: 10.3390/cancers13205208
  • Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
    Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR.
    Cancer Discov. 2020 Mar;10(3):440-459. doi: 10.1158/2159-8290.CD-19-0116. Epub 2020 Jan 8.
    PMID: 31915197 Free PMC article. PMCID: PMC7275250 DOI: 10.1158/2159-8290.CD-19-0116
  • An Autologous culture model of nodal B cell lymphoma identifies ex vivo determinants of response to bispecific antibodies
    Roider T, Brinkmann BJ, Kim V, Knoll M, Kolb C, Roessner PM, Bordas M, Dreger P, Müller-Tidow C, Huber W, Seiffert M, Dietrich S. Blood Adv. 2021 in press PMID: 34587238 DOI: 10.1182/bloodadvances.2021005400
  • Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level.
    Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N, Stolarczyk M, Mallm JP, Rabe R, Bruch PM, Balke-Want H, Hundemer M, Rippe K, Goeppert B, Seiffert M, Brors B, Mechtersheimer G, Zenz T, Peifer M, Chapuy B,  Schlesner M, Müller-Tidow C, Fröhling S,  Huber W,  Anders SA,  Dietrich S. 
    Nature Cell Biology. 2020 PMID: 32541878 DOI: 10.1038/s41556-020-0532-x

 

 

2020

 

Aggressive Lymphome

  • Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines.
    Wirth A, Mikhaeel NG, Pauline Aleman BM, Pinnix CC, Constine LS, Wilmot JP, Ricardi U, Illidge TM, Eich HT, Hoppe BS, Dabaja B, Ng AK, Kirova Y, Berthelsen AK, Dieckmann K, Yahalom J, Specht L.
    Int J Radiat Oncol Biol Phys. 2020 Apr 6:S0360-3016(20)30943-3. DOI: 10.1016/j.ijrobp.2020.03.019. Online ahead of print.PMID: 32272184 Review. No abstract available.

  • Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG.
    Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang RW, Dickinson M, Ng A, Roberts KB, Gao S, Balogh AG, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras JP, Wright C, Kelsey CR, Brady JL, Mikhaeel NG, Hoppe BS, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine LS, Eich HT, Wirth A, Hoppe RT.
    Blood. 2020 Mar 25:blood.2019003877. DOI: 10.1182/blood.2019003877. Online ahead of print. PMID: 32211877

  • The Conditional Survival of Patients with Relapsed DLBCL after Auto-Transplant: A Subgroup Analysis of LY.12 and CORAL
    Assouline S, Li S, Gisselbrecht C, Fogarty P, Hay A, Van Den Neste E, Shepherd L, Schmitz N, Baetz T, Keating A, Robinson KS, Seftel M, Stelitano C, Djurfeldt M, Meyer R, Chen B, Crump M
    Blood Advances 2020 (in press)

  • Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosee P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson A-M, von Wangenheim U, Burkard U, Berk A, Schmitz N.
    Investigational New Drugs 2020 (in press)

  • International Prognostic Indices in Diffuse Large B-cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI
    Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, Flament J, Flowers C, Shi Q, Schmitz N.
    Blood. 2020 Jun 4;135(23):2041-2048. DOI: 10.1182/blood.2019002729.Blood. 2020.PMID: 32232482

  • A 70% Cut-Off for MYC Protein Expression in Diffuse Large B Cell Lymphoma Identifies a High-Risk Group of Patients
    Ziepert M, Lazzi S, Santi R, Vergoni F, Granai M, Mancini V, Staiger A, Horn H, Löffler M, Pöschel V, Held G, Wulf G, Trümper LH, Schmitz N, Rosenwald A, Sabattini E, Naresh KN, Stein H, Ott G, Leoncini L.Ziepert M, et al.
    Haematologica. 2020 Feb 13:haematol.2019.235556. DOI: 10.3324/haematol.2019.235556. Online ahead of print.Haematologica. 2020. PMID: 32054654

  • Emed Demonstrator Project; German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
    Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AC, Möller P, Hansmann ML, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, Spang R;
    Leukemia. 2020 Feb;34(2):543-552. DOI: 10.1038/s41375-019-0573-y. Epub 2019 Sep 17. PubMed PMID: 31530861.

     

 

Follikuläres Lymphom

  • Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.
    Staiger AM, Hoster E, Jurinovic V, Winter S, Leich E, Kalla C, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Weigert O, Hiddemann W, Herfarth K, Rosenwald A, Engelhard M, Ott G, Horn H.

    Blood. 2020 Jan 16;135(3):181-190. DOI: 10.1182/blood.2019000560 PubMed PMID: 31697802

  • Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients.
    Elsayad K, Reinartz G, Oertel M, Rehn S, Eismann J, Scobioala S, Berssenbrügge H, Eter N, Weishaupt C, Schmidt HH, Friedrichs B, Grünewald I, Hartmann W, Lenz G, Wardelmann E, Willich N, Eich HT.
    Strahlenther Onkol. 2020 Feb;196(2):117-125. DOI: 10.1007/s00066-019-01538-2. Epub 2019 Nov 15. PMID: 31732783

  • HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.
    Stevens WBC, Bakunina K, Cuijpers M, Chamuleau M, Beeker A, Fijnheer R, Hebart H, Visser HPJ, Doorduijn JK, Linton K, Dreyling M, de Jong D, Kersten MJ.
    Hemasphere. 2020 Jan 3;4(1):e325

 

Indolente Lymphome

  • De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma.
    Oertel M, Elsayad K, Weishaupt C, Steinbrink K, Eich HT.
    Strahlenther Onkol. 2020 Feb;196(2):126-131. DOI: 10.1007/s00066-019-01541-7. Epub 2019 Nov 22. PMID: 31758232 English

  • Marginalzonenlymphom

    • Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. E Zucca, L Arcaini, C Buske, P W Johnson, M Ponzoni, M Raderer, U Ricardi, A Salar, K Stamatopoulos, C Thieblemont, A Wotherspoon, M Ladetto for the ESMO Guidelines Committee. Ann Oncol, 31 (1), 17-29 Jan 2020

  • M. Waldenström

    • Bruton Tyrosine-Kinase Inhibitor on the Rise: Acalabrutinib in Waldenström Macroglobulinemia. Christian Buske. Lancet Haematol, 7 (2), e85-e86 Feb 2020, 7 (2), e85-e86 Feb 2020

 

Mantelzelllymphome

  • Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
    Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G, Ferrante M, Genuardi E, Mantoan B, Villarese P, Cheminant M, Starza ID, Ciabatti E, Bomben R, Jimenez C, Callanan M, Abdo C, Eckert C, Ribrag V, Cortelazzo S, Dreyling M, Hermine O, Delfau-Larue MH, Pott C, Ladetto M, Ferrero S, Macintyre E.
    Hemasphere. 2020 Apr 3;4(2):e347

  • Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.
    Croci GA, Hoster E, Beà S, Clot G, Enjuanes A, Scott DW, Cabeçadas J, Veloza L, Campo E, Clasen-Linde E, Goswami RS, Helgeland L, Pileri S, Rymkiewicz G, Reinke S, Dreyling M, Klapper W.
    Virchows Arch. 2020 Jan 23. DOI: 10.1007/s00428-020-02750-7. [Epub ahead of print] PubMed PMID: 31975037.

  • Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
    Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH.
    J Clin Oncol. 2020 Jan 20;38(3):248-256. DOI: 10.1200/JCO.19.01294. Epub 2019 Dec 5. PubMed PMID: 31804876.

 

T-Zell-Lymphome

  • Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome.
    Khaled Elsayad, Rudolf Stadler, Kerstin Steinbrink, Hans Theodor Eich

    J Dtsch Dermatol Ges. 2020 Mar;18(3):193-197. DOI: 10.1111/ddg.14044. Epub 2020 Feb 20. PMID: 32077638 Review

  • Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome.
    Elsayad K, Kroeger K, Greve B, Moustakis C, Assaf C, Stadler R, Lenz G, Weishaupt C, Eich HT.
    Strahlenther Onkol. 2020 Jan;196(1):77-84. DOI: 10.1007/s00066-019-01517-7. Epub 2019 Oct 7. PMID: 31591658 English.

  • Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis.
    Elsayad K, Oertel M, König L, Hüske S, Le Ray E, Meheissen MAM, Elsaid AA, Elfaham E, Debus J, Kirova Y, Herfarth K, Eich HT.
    Cancers (Basel). 2020 Mar 13;12(3):676. DOI: 10.3390/cancers12030676. PMID: 32183106 Free PMC article.

  • Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
    Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Wilhelm C, Pezzutto A, Zijlstra JM, Neste EVD, Lugtenburg PJ, Doorduijn JK, Gelder MV, van Imhoff GW, Zettl F, Braulke F, Nickelsen M, Glass B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N, Trümper L; ACT-2 study investigators.Wulf GG, et al.
    Leukemia. 2020 May 7. DOI: 10.1038/s41375-020-0838-5. Online ahead of print.Leukemia. 2020.PMID: 32382083

 

Reducing Bureaucracy in Clinical Research: A Call for Action.
Gribben J, Macintyre E, Sonneveld P, Doorduijn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S, Dreyling M.
Hemasphere. 2020 Feb 26;4(2):e352

 

 

2019

 

Agressive Lymphome

  • Renaissance of Radiotherapy in Intestinal Lymphoma? 10-year Efficacy and Tolerance in Multimodal Treatment of 134 patients. Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials.
    Reinartz G, Molavi C, Liersch R, Ullerich H, Hering D, Willborn K, Schultze J, Micke O, Rübe C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M, Möller P, Neubauer A, Wilhelm M, Lenz G, Berdel WE, Willich N, Eich HT.
    The Oncologist 2020 May;25(5):e816-e832. DOI: 10.1634/theoncologist.2019-0783. Epub 2020 Mar 27.
  • A Novel Lymphoma-Associated Macrophage Interaction Signature (LAMIS) Provides Robust Risk Prognostication in Diffuse Large B-Cell Lymphoma Clinical Trial Cohorts of the DSHNHL
    Staiger A, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AG, Möller P, Hansmann M-L, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, Spang R for the German High Grade Non-Hodgkin`s Lymphoma Study Group (DSHNHL) and the Emed Demonstrator Project
    Leukemia 2019 DOI:10.1038/s41375-019-0573-y
  • Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
    Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.Rosenwald A, et al.
    J Clin Oncol. 2019 Dec 10;37(35):3359-3368. DOI: 10.1200/JCO.19.00743. Epub 2019 Sep 9.J Clin Oncol. 2019. PMID: 31498031
  • The impact of SOCS1 mutations in diffuse large B-cell lymphoma
    Mellert K, Martin M, Lennerz JK, Lüdeke M, Staiger AM, Kreuz M, Löffler M, Schmitz N, Trümper L, Feller AC, Hartmann S, Hansmann ML, Klapper W, Stein H, Rosenwald A, Ott G, Ziepert M, Möller P.Mellert K, et al.
    Br J Haematol. 2019 Dec;187(5):627-637. DOI: 10.1111/bjh.16147. Epub 2019 Aug 12.Br J Haematol. 2019. PMID: 31407320
  • Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party.
    Hübel K, Re A, Boumendil A, Finel H, Hentrich M, Robinson S, Wyen C, Michieli M, Kanfer E, Diez-Martin JL, Balsalobre P, Vincent L, Schroyens W, Santasusana JMR, Kröger N, Schiel X, Cwynarski K, Esquirol A, Sousa AB, Cattaneo C, Montoto S, Dreger P
    Bone Marrow Transplant 54: 1625-1632, 2019.
  • FLYER Trial Investigators; German Lymphoma Alliance. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M;
    Lancet. 2019 Dec 21;394(10216):2271-2281. DOI: 10.1016/S0140-6736(19)33008-9. PubMed PMID: 31868632.
  • ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
    Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L, Weisenburger DD, Rosenwald A, Nakamura S, Ziepert M, Maurer MJ, Bast M, Armitage JO, Vose JM, Tilly H, Jais JP, Savage KJ.Sibon D, et al.
    Haematologica. 2019 Dec;104(12):e562-e565. DOI: 10.3324/haematol.2018.213512. Epub 2019 Apr 19.Haematologica. 2019. PMID: 31004022
  • Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
    Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, Schmidt C, Ruebe C, Loeffler M, Pfreundschuh M, Rosenwald A, Glass B, Lenz G, Schmitz N; German high-grade lymphoma Study Group.Friedrichs B, et al.
    Br J Haematol. 2019 Mar;184(5):760-768. DOI: 10.1111/bjh.15710. Epub 2018 Dec 5.Br J Haematol. 2019. PMID: 30520013
  • Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs.
    Hübel K, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, Milkovich G, Mohty M
    Bone Marrow Transplant 54: 123-129, 2019

 

Follikuläres Lymphom

  • Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG
    Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT and Mikhaeel NG.
    Blood 2019; 133: 237-245. DOI: 10.1182/blood-2018-04-843540.

  • The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG).
    Mikhaeel NG, Milgrom SA, Terezakis S, Berthelsen AK, Hodgson D, Eich HT, Dieckmann K, Qi SN, Yahalom J, Specht L.
    Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):501-512. doi: 10.1016/j.ijrobp.2019.02.001. Epub 2019 Feb 11.PMID: 30763664 Review.

  • Salvage treatment and survival for relapsed follicular lymphoma following primary radiotherapy: A collaborative study on behalf of ILROG.
    Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng A, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich H, Bratman S, Constine LS, Suh CO, Dabaja B, El-Galaly T, Hodgson D, Ricardi U, Yahalom J, Mikhaeel NG, Hoppe RT.
    Int J Radiat Oncol Biol Phys 2019 Mar 8. pii: S0360-3016(19)30317-7. DOI: 10.1016/j.ijrobp.2019.03.004. Epub 2019 Mar 8.

  • Low number of intrafollicular T cells may predict favourable responseto rituximab?based immuno?chemotherapy in advanced follicularlymphoma: a secondary analysis of a randomized clinical trial
    Laura Budau, Christian Wilhelm, Roland Moll, Jörg Jäkel, Carsten Hirt, Gottfried Dölken, Georg Maschmeyer, Ellen Neubauer, Konstantin Strauch, Andreas Burchert, Michael Herold, Andreas Neubauer
    Journal of Cancer Research and Clinical Oncology (2019) 145:2149–2156

  • Association of Early Disease Progression and Very Poor Survival in the GALLIUM Study in Follicular Lymphoma: Benefit of Obinutuzumab in Reducing the Rate of Early Progression
    John F Seymour, Robert Marcus, Andrew Davies, Eve Gallop-Evans, Andrew Grigg, Andrew Haynes, Michael Herold, Thomas Illmer, Herman Nilsson-Ehle, Martin Sökler, Ulrich Dünzinger, Tina Nielsen, Aino Launonen, Wolfgang Hiddemann
    Hematologica 2019 Jun;104(6):1202-1208. 

  • Impact of age on clinical risk scores in follicular lymphoma.
    Alig S, Jurinovic V, Pastore A, Haebe S, Schmidt C, Zoellner AK, Dreyling M, Unterhalt M, Hoster E, Hiddemann W, Weigert O.
    Blood Adv. 2019 Apr 9;3(7):1033-1038.
    DOI: 10.1182/bloodadvances.2019032136. PubMed PMID: 30940638; PubMed Central PMCID: PMC6457218

  • Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
    König L, Dreyling M, Dürig J, Engelhard M, Hohloch K, Viardot A, Witzens-Harig M, Kieser M, Klapper W, Pott C, Herfarth K.
    Trials. 2019 Aug 30;20(1):544 (IF 1,98)
  • Localized and Advanced Stage Follicular Lymphomas Differ in their Gene Expression Profiles
    Staiger AM, Hoster E, Jurinovic V, Winter S, Leich E, Kalla C, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M
    Blood. 2019 Oct 10. [Epub ahead of print] (IF 16,56)

 

Indolente Lymphome

  • Favorable radiation field decrease in gastric marginal zone lymphoma – Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL).
    Reinartz G, Pyra RP, Lenz G, Liersch R, Stüben G, Micke O, Willborn K, Hess CF, Probst A, Fietkau R, Jany R, Schultze J, Rübe C, Hirt C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M, Möller P, Neubauer A, Wilhelm M, Willich N, Berdel WE, Eich HT.
    Strahlenther Onkol 2019; 195 (6): 544-557. DOI: 10.1007/s00066-019-01446-5. Epub 2019 Mar 11.
  • Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients.
    Elsayad K*, Reinartz G*, Oertel M, Rehn S, Eismann J, Scobioala S, Berssenbrügge H, Eter N, Weishaupt C, Schmidt HH, Friedrichs B, Grünewald I, Hartmann W, Lenz G, Wardelmann E, Willich N, Eich HT.
    Strahlenther Onkol 2019; Nov 15. DOI: 10.1007/s00066-019-01538-2. Epub 2019 Nov 15. *KE and GR contributed equally.
  • Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.
    Vidal L, Gurion R, Shargian L, Dreyling M, Gafter-Gvili A. 
    Br J Haematol. 2019 Jul;186(2):234-242
  • Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
    Clin Oncol. 2019 Nov 1;37(31):2835-2845. DOI: 10.1200/JCO.19.00964. Epub 2019 Sep 10. PMID: 31498753

 

Mantelzelllymphome

  • Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
    Morello L, Rattotti S, Giordano L, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, Ferrero S, Szymczyk M, Aurer I, El-Galaly TC, Di Rocco A, Visco C, Carli G, Defrancesco I, Carlo-Stella C, Dreyling M, Santoro A, Arcaini L
    Hemasphere. 2019 Dec 16;4(1):e302.
  • Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
    Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A
    Br J Haematol. 2019 Feb;184(4):616-624 (IF 5,13)
  • Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
    Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U;
    Br J Haematol. 2019 Jun;185(5):940-944
     

T-Zell-Lymphome

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
    Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L, ECHELON-2 Study Group (2019)
    LANCET 393(10168): 229-240, DOI: 10.1016/S0140-6736(18)32984-2

 

Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017
Rudolf Weide, Stefan Feiten, Geothy Chakupurakal, Vera Friesenhahn, Kristina Kleboth, Hubert Köppler, Julia Lutschkin, Christoph van Roye, Jörg Thomalla & Jochen Heymanns
Leukemia & Lymphoma DOI: 10.1080/10428194.2019.1680840

2018

Aggressive Lymphome

  • Structured reporting adds clinical value in primary CT staging of diffuse large B-cell lymphoma. Schoeppe F, Sommer WH, Nörenberg D, Verbeek M, Bogner C, Westphalen CB, Dreyling M, Rummeny EJ, Fingerle AA. Eur Radiol, 2018 Epub
  • The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S. Leukemia, 2018 Epub
  • Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. Dunleavy K, Erdmann T, Lenz G. Cancer Treat Rev, 2018, Apr;65:41-46
  • Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL. Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M, Dreyling M, Lenz G, Gaumann A. Leuk Lymphoma, 2018, 59(5):1260-1263
  • A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM. Nature, 2018 Epub
  • Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining. Reinke S, Richter J, Fend F, Feller A, Hansmann ML, Hüttl K, Oschlies I, Ott G, Möller P, Rosenwald A, Stein H, Altenbuchinger M, Spang R, Klapper W. Virchows Arch, 2018
  • Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Nat Med, 2018, May;24(5):679-690
  • Aggressive B-cell lymphomas: Recommendations from the German Panel of Reference Pathologists in the Competence Network on Malignant Lymphomas on diagnostic procedures according to the current WHO classification, update 2017. Klapper W, Fend F, Feller A, Hansmann ML, Möller P, Stein H, Rosenwald A, Ott G. Pathologe, 2018 Epub
  • Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM. N Engl J Med, 2018, 378(15):1396-1407
  • Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Horn H, Kohler C, Witzig R, Kreuz M, Leich E, Klapper W, Hummel M, Loeffler M, Trümper L, Spang R, Rosenwald A, Ott G. Haematologica, 2018, Epub
  • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A. Blood, 2018, 131(18):2060-2064
  • Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR.Shi Q, et al.
    J Clin Oncol. 2018 Sep 1;36(25):2593-2602. DOI: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.J Clin Oncol. 2018. PMID: 29975624
  • Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

    Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B.Maurer MJ, et al.
    Ann Oncol. 2018 Aug 1;29(8):1822-1827. DOI: 10.1093/annonc/mdy203.Ann Oncol. 2018. PMID: 29897404

  • Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.

    Hohloch K, Altmann B, Pfreundschuh M, Loeffler M, Schmitz N, Zettl F, Ziepert M, Trümper L.Hohloch K, et al.
    Br J Haematol. 2018 Jan;180(2):236-245. DOI: 10.1111/bjh.15029. Epub 2017 Nov 28.Br J Haematol. 2018. PMID: 29193018

  • Doubling Rituximab in high-risk patients with aggressive B-cell lymphomas in the DENSE-R MegaCHOEP trial
    Friedrichs B, Nickelsen M, Ziepert M et al.
    Brit J Haematol 2018 (https:// doi.org./ 10.1111/ bjh.15710)

 

 

Follikuäres Lymphom

  • Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study. Herfarth K, Borchmann P, Schnaidt S, Hohloch K, Budach V, Engelhard M, Viardot A, Engenhart-Cabillic R, Keller U, Reinartz G, Eich HT, Witzens-Harig M, Hess CF, Dörken B, Dürig J, Wiegel T, Hiddemann W, Hoster E, Pott C, Dreyling M.  Hemasphere. 2018 Nov 30;2(6):e160
  • Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.
    Hellmuth JC, Louissaint A Jr, Szczepanowski M, Haebe S, Pastore A, Alig S, Staiger AM, Hartmann S, Kridel R, Ducar MD, Koch P, Dreyling M, Hansmann ML, Ott G, Rosenwald A, Gascoyne RD, Weinstock DM, Hiddemann W, Klapper W, Weigert O.
    Blood. 2018 Oct 18;132(16):1695-1702 (IF 13,16)
  • New treatment options in advanced stage follicular lymphoma. Hübel K, Salles G, Marcus R, Zinzani PL, Dreyling M: Hemasphere 6: p e 156, 2018.
  • The diagnosis and treatment of primary CNS lymphoma – An interdisciplinary challenge.
    Von Baumgarten L, Illerhaus G, Korfel A, Schlegel U, Deckert M, Dreyling M
    Dtsch Arztebl Int 2018, 115: 419-426 (IP 4,26)

 

Indolente Lymphome

  • Immunochemotherapy with Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. J Clin Oncol. 2018
  • Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, Dreger P, Dreyling M, Hiddemann W, Unterhalt M, Hoster E, Weigert O. Biol Blood Marrow Transplant. 2018
  • Impact of age on genetics and treatment efficacy in follicular lymphoma. Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner A, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O. Haematologica. 2018
  • FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R. Blood. 2018
  • ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients. Hutchings M, Ladetto M, Buske C, de Nully Brown P, Ferreri AJM, Pfreundschuh M, Schmitz N, Balari AS, van Imhoff G, Walewski J; ESMO Lymphoma Consensus Conference Panel Members. Ann Oncol. 2018
  • A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C. Future Oncol. 2018
  • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. N Engl J Med. 2018
  • Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. Ann Oncol. 2018
  • ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trnený M, Wedding U, Fields P; ESMO Lymphoma Consensus Conference Panel Members. Ann Oncol, 2018, 29(3):544-562
  • Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. J Clin Oncol, 2018 Epub
  • The role of stem cell transplantation in follicular lymphoma. Hess G. Best Pract Res Clin Haematol, 2018, 31(1):31-40
  • Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. Maurus K, Appenzeller S, Roth S, Kuper J, Rost S, Meierjohann S, Arampatzi P, Goebeler M, Rosenwald A, Geissinger E, Wobser M. J Invest Dermatol, 2018, 138(7):1573-1581
  • The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. Zamò A, Pischimarov J, Horn H, Ott G, Rosenwald A, Leich E. Br J Haematol, 2018, 180(3):391-394

 

Mantelzelllymphome

  • Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge
    Dreyling M, Klapper W, Rule S.
    Blood. 2018 Dec 27;132(26):2722-2729 (IF 13,16)
  • Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle-cell Lymphoma. Buske C, Dreyling M. Dtsch Med Wochenschr. 2018 Jan;143(1):46-51. doi: 10.1055/s-0043-124004. Epub 2018
  • Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. Agarwal R, Dawson MA, Dreyling M, Tam CS. Leuk Lymphoma, 2018, 1-13
  • Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. Leukemia, 2018 Epub
  • Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. N Engl J Med, 2018, 378(13):1211-1223
  • Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, Dreyling M, Klapper W. Blood. 2018, 131(4):417-420
  • Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Br J Haematol, 2018, 181(3):306-319
  • A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma. Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E. Blood, 2018 Epub
  • CD40L mediated alternative NF?B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A. Cell Death Dis, 2018, 9(2):86
  • Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione

    Italiana Linfomi and the Mantle Cell Lymphoma Network. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019 Jun;185(5):940-944.
    DOI: 10.1111/bjh.15643. Epub 2018 Nov 8. PubMed PMID: 30407625.

  • Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A.
    Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. Br J Haematol. 2019 Feb;184(4):616-624.
    DOI: 10.1111/bjh.15519. Epub 2018 Aug 10. PubMed PMID: 30095158; PubMed Central PMCID: PMC6361690.

 

T-Zell Lymphome

  • Sequential chemotherapy/ radiotherapy  was comparable with concurrent chemoradiotherapy for stage I/ II NK/ T-cell lymphoma Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, Do YR, Mun YC, Lee SR, Shin HJ, Suh C, Chuang SS, Lee YS, Lim ST, Izutsu K, Suzuki R, Relander T, d`Amore F, Schmitz N, Jaccard A, Kim, WS
    Ann Oncol 2018; 29, 256-263
  • Allogeneic hematopoietic stem cell transplantation (HSCT) for T-cell lymphomas. Schmitz N, Lenz G, Stelljes M. Blood, 2018 Epub
  • Bispecific antibodies in haematological malignancies. Viardot A, Bargou R. Cancer Treat Rev, 2018, 65:87-95